Innovative Therapeutics in Oncology and Neuroscience
Efgartigimod
No Clinically Meaningful Reductions in Albumin and No Increases in LDL Cholesterol
60
50
40
30
20
LLN1
ADAPT Study
ADAPT+ Study
Total Albumin
ULN1
60
Total albumin,
Mean (SD). g/L
65432
40
Total Albumin
50
30
20
10
10
0
0
Week 012 3
4 5
6
7
8 9 10 11 12
Week 012
3
5
5
LDL Cholesterol
Total albumin,
Mean (SD). g/L
Total cholesterol,
Mean (SD). mmol/L
+
3
2
0
Week
0 1
2
3
High: >4.10 mmol/L2
Optimal: <2.60 mmol/L2
456789
⚫EFG
-PBO
Total cholesterol,
Mean (SD). mmol/L
+
3
2
7
Approved
ULN1
LLN1
LDL Cholesterol
High: >4.10 mmol/L2
11
Optimal: <2.60 mmol/L²
0
10 11
12
Week
0 1 2 3
7
39
Abbreviations: acetylcholine receptor autoantibody (AChR-Ab), low-density lipoprotein (LDL), lower limit of normal (LLN), upper limit of normal (ULN).
Note: (1) Reference values are based on Kratz A, N Engl J Med, 2004; 351(15): 1548-1563; (2) Reference values are based on https://www.mayoclinic.org/tests-procedures/cholesterol-test/about/pac-20384601.
3
4
5
11
Clinical Data -
AutoimmuneView entire presentation